2013-04-01 10:25:43 - New Pharmaceuticals market report from Global Markets Direct: "Crohn's Disease - Pipeline Review, H1 2013"
Global Markets Direct's, 'Crohn's Disease - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Crohn's Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Crohn's Disease. Crohn's Disease - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated
* A snapshot of the global therapeutic scenario for Crohn's Disease.
* A review of the Crohn's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Crohn's Disease pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.
Full Report Details at
- www.fastmr.com/prod/556293_crohns_disease_pipeline_review_h1_201 ..
Reasons to buy
* Identify and understand important and diverse types of therapeutics under development for Crohn's Disease.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Crohn's Disease pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Partial Table of Contents:
Table of Contents
Table of Contents
List of Tables
List of Figures
Global Markets Direct Report Coverage
Crohn's Disease Overview
An Overview of Pipeline Products for Crohn's Disease
Crohn's Disease Therapeutics under Development by Companies
Crohn's Disease Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Mid Clinical Stage Products
Early Clinical Stage Products
Discovery and Pre-Clinical Stage Products
Crohn's Disease Therapeutics - Products under Development by Companies
Crohn's Disease Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Crohn's Disease Therapeutics Development
Bristol-Myers Squibb Company
Johnson & Johnson
Osiris Therapeutics, Inc.
AbGenomics International, Inc.
Novo Nordisk A/S
Cytokine PharmaSciences, Inc.
Takeda Pharmaceutical Company Limited
Axcan Pharma Inc.
Teva Pharmaceutical Industries Limited
Zeria Pharmaceutical Co Ltd
iCo Therapeutics Inc.
Enzo Biochem, Inc.
NPS Pharmaceuticals, Inc.
ProMetic Life Sciences Inc.
Pluristem Therapeutics Inc.
Alba Therapeutics Corporation
Viron Therapeutics, Inc.
Farmacija d.o.o. Tuzla
Altor BioScience Corporation
Alder Biopharmaceuticals Inc.
Coronado Biosciences, Inc.
Selexys Pharmaceuticals Corporation
TcL Pharma SAS
Winston Pharmaceuticals, Inc.
S.L.A. Pharma AG
Stelic Institute & Co.
Centocor Ortho Biotech, Inc.
Immune Technologies and Medicine
Crohn's Disease - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
laquinimod sodium - Drug Profile
tofacitinib - Drug Profile
eldelumab - Drug Profile
PDA-001 - Drug Profile
tetomilast - Drug Profile
remestemcel-L - Drug Profile
PF-04236921 - Drug Profile
teduglutide - Drug Profile
TNF-Kinoid - Drug Profile
NI-0401 - Drug Profile
vedolizumab - Drug Profile
mercaptopurine - Drug Profile
ustekinumab - Drug Profile
clazakizumab - Drug Profile
vercirnon sodium - Drug Profile
vidofludimus - Drug Profile
SGX-203 - Drug Profile
SelK2-Anti-PSGL-1 - Drug Profile
OvaSave - Drug Profile
MP-196 - Drug Profile
ALT-836 - Drug Profile
larazotide acetate - Drug Profile
STNM-01 - Drug Profile
infliximab - Drug Profile
GED-0301 - Drug Profile
SQ-641 - Drug Profile
VT-346 - Drug Profile
Xpro-1595 - Drug Profile
budesonide - Drug Profile
bertilimumab - Drug Profile
mesalamine - Drug Profile
zucapsaicin Capsule - Drug Profile
Alequel - Drug Profile
semapimod - Drug Profile
PBI-1737 - Drug Profile
TSO - Drug Profile
Full Table of Contents is available at:
About Global Markets Direct
Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
For more information about these or related research reports, please visit our website at www.fastmr.com
or call us at 1.800.844.8156.